Rituximab Suppliers & Bulk Manufacturers

Available Forms: IV Infusion; Subcutaneous

Available Strengths: IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL

Reference Brands: Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US)

Category: Oncology Cancer Care

Rituximab is available in IV Infusion; Subcutaneous and strengths such as IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Rituximab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Rituximab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Rituximab is a monoclonal antibody used for treating various hematologic cancers and autoimmune disorders. It targets CD20 on B cells, facilitating their destruction, and is effective for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Available under Rituxan® in the US and MabThera® in the EU, Rituximab is supplied in IV infusion (100 mg/10 mL, 500 mg/50 mL) and subcutaneous (1400 mg/11 mL) formulations. Manufactured in GMP-compliant facilities, Rituximab is a trusted treatment option for oncology and autoimmune disease management, offering reliable solutions for pharma distributors across EU and US markets.